IDO1 and tuberculosis: With IDO-1 inhibitors in clinical trials (73), management of TB disease might benefit from simultaneous therapeutic inhibition of IDO-1 activity to enhance Th17 cell responses, particularly in PWH where HIV further enhances tryptophan catabolism via the kynurenine pathway.